The effects of glucose-insulin-potassium solution and BN 52021 in intestinal ischemia-reperfusion injury

Vascular and Endovascular Surgery

Volumn 37, Issue 5, 2003, Pages 345-351

  Aldemir, Mustafa ^a   Gürel, Ahmet ^b   Büyükbayram, Hüseyin ^b   Taçyildiz, Ibrahim ^b  

^a DICLE UNIVERSITY   (Turkey)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

GINKGOLIDE B; GLUCOSE; INSULIN; MALONALDEHYDE; POTASSIUM; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ILEUM; INTESTINE ISCHEMIA; MALE; NONHUMAN; RAT; RAT STRAIN; REPERFUSION; REPERFUSION INJURY; SCORING SYSTEM;

ANIMALS; DISEASE MODELS, ANIMAL; DITERPENES; GINKGOLIDES; GLUCOSE; INJURY SEVERITY SCORE; INSULIN; INTESTINAL DISEASES; LACTONES; MALE; POTASSIUM; PROBABILITY; RATS; RATS, SPRAGUE-DAWLEY; REFERENCE VALUES; REPERFUSION INJURY; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0141523104     PISSN: 15385744     EISSN: None     Source Type: Journal    
DOI: 10.1177/153857440303700506     Document Type: Article

References (42)

1. Megison SM, Horton JW, Chao H, et al: A new model for intestinal ischemia in the rat. J Surg Res 49:168-173, 1990.
2. Megison SM, Horton JW, Chao H, et al: Prolonged survival and decreased mucosal injury after low-dose enteral allopurinol prophylaxis in mesenteric ischemia. J Pediatr Surg 25:917-921, 1990.
3. Caplan MS, MacKendrick W: Necrotizing enterocolitis: A review of pathogenetic mechanisms and implications for prevention. Pediatr Pathol 13:357-369, 1993.
4. Kleinhaus S, Weinberg G, Gregor MB: Necrotizing enterocolitis in infancy. Surg Clin North Am 72:261-276, 1992.
5. Schiller HJ, Reilly PM, Bulkley GB: Tissue perfusion in critical illnesses. Antioxidant therapy. Crit Care Med 21:S92-S102, 1993.
6. Minor T, Isselhard W, Yamaguchi T: Involvement of platelet activating factor in microcirculatory disturbances after global hepatic ischemia. J Surg Res 58:536-540, 1995.
7. Braquet P, Esanu A, Buisine E, et al: Recent progress in ginkgolide research. Med Res Rev 11:295-355, 1991.
8. Loucks EB, Qayumi AK, Godin DV, et al: Therapeutic potential of platelet-activating factor antagonism in the management of myocardial infarction. Can J Cardiol 16:497-504, 2000.
9. Liu XH, Eun BL, Silverstein FS, et al: The platelet-activating factor antagonist BN 52021 attenuates hypoxic-ischemic brain injury in the immature rat. Pediatr Res 40:797-803, 1996.
10. Suzuki S, Serizawa A, Sakaguchi T, et al: The roles of platelet-activating factor and endothelin-1 in renal damage after total hepatic ischemia and reperfusion. Transplantation 69:2267-2273, 2000.
11. Stammberger U, Carboni GL, Hillinger S, et al: Combined treatment with endothelin- and PAF-antagonists reduces posttransplant lung ischemia/ reperfusion injury. J Heart Lung Transplant 18:862-868, 1999.
12. Braquet P, Paubert-Braquet M, Koltai M, et al: Is there a case for PAF antagonists in the treatment of ischemic states? Trends Pharmacol Sci 10:23-30, 1989.
13. McKenna DJ, Jones K, Hughes K: Efficacy, safety, and use of ginkgo biloba in clinical and preclinical applications. Altern Ther Health Med 7:70-86, 88-90, 2001.
14. Oliver MF, Opie LH: Effects of glucose and fatty acids on myocardial ischaemia and arrhythmias. Lancet 343:155-158, 1994.
15. Henderson AH, Most AS, Parmley WW, et al: Depression of myocardial contractility in rats by free fatty acids during hypoxia. Circ Res 26:439-449, 1970.
16. Apstein CS: Glucose-insulin-potassium for acute myocardial infarction: Remarkable results from a new prospective, randomized trial. Circulation 98:2223-2226, 1998.
17. McDaniel HG, Papapietro SE, Rogers WJ, et al: Glucose-insulin-potassium induced alterations in individual plasma free fatty acids in patients with acute myocardial infarction. Am Heart J 102:10-15, 1981.
18. Stanley AW Jr, Moraski RE, Russell RO, et al: Effects of glucose-insulin-potassium on myocardial substrate availability and utilization in stable coronary artery disease. Studies on myocardial carbohydrate, lipid and oxygen arterial-coronary sinus differences in patients with coronary artery disease. Am J Cardiol 36:929-937, 1975.
19. Davi G, Catalano I, Averna M, et al: Thromboxane biosynthesis and platelet function in type II diabetes mellitus. N Engl J Med 322:1769-1774, 1990.
20. Jain SK, Nagi DK, Slavin BM, et al: Insulin therapy in type 2 diabetic subjects suppresses plasminogen activator inhibitor (PAI-1) activity and proinsulin-like molecules independently of glycaemic control. Diabet Med 10:27-32, 1993.
21. Chiu CJ, Scott HJ, Gurd FN: Intestinal mucosal lesion in low-flow states. II. The protective effect of intraluminal glucose as energy substrate. Arch Surg 101:484-488, 1970.
22. Yagi K: Lipid peroxides in hepatic, gastrointestinal, and pancreatic diseases. In: Free Radicals in Diagnostic Medicine, ed. by Armstrong D. New York: Plenum Press, 1994, pp 165-169.
23. Sun Z, Wang X, Deng X, et al: Beneficial effects of lexipafant, a PAF antagonist on gut barrier dysfunction caused by intestinal ischemia and reperfusion in rats. Dig Surg 17:57-65, 2000.
24. Minor T, Isselhard W: Platelet-activating factor antagonism enhances the liver's recovery from warm ischemia in situ. J Hepatol 18:365-368, 1993.
25. Sun Z, Wang X, Lasson A, et al: Effects of inhibition of PAF, ICAM-1 and PECAM-1 on gut barrier failure caused by intestinal ischemia and reperfusion. Scand J Gastroenterol 36:55-65, 2001.
26. Souza DG, Cara DC, Cassali GD, et al: Effects of the PAF receptor antagonist UK74505 on local and remote reperfusion injuries following ischaemia of the superior mesenteric artery in the rat. Br J Pharmacol 131:1800-1808, 2000.
27. Sun Z, Wang X, Lasson A, et al: Roles of platelet-activating factor, interleukin-1 beta and interleukin-6 in intestinal barrier dysfunction induced by mesenteric arterial ischemia and reperfusion. J Surg Res 87:90-100, 1999.
28. Apstein CS, Taegtmeyer H: Glucose-insulin-potassium in acute myocardial infarction: The time has come for a large, prospective trial. Circulation 96:1074-1077, 1997.
29. Madesh M, Ramachandran A, Pulimood A, et al: Attenuation of intestinal ischemia/reperfusion injury with sodium nitroprusside: Studies on mitochondrial function and lipid changes. Biochim Biophys Acta 1500:204-216, 2000.
30. Das DK, Maulik N: Antioxidant effectiveness in ischemia-reperfusion tissue injury. Methods Enzymol 233:601-610, 1994.
31. Floyd RA: Role of oxygen free radicals in carcinogenesis and brain ischemia. FASEB J 4:2587-2597, 1990.
32. Rangan U, Bulkley GB: Prospects for treatment of free radical-mediated tissue injury. Br Med Bull 49:700-718, 1993.
33. Sieunarine K, Wangoo D, Langton S, et al: Blood lipid profile in ischaemia reperfusion injury. Aust NZ J Surg 69:224-228, 1999.
34. Jonassen AK, Aasum E, Riemersma RA, et al: Glucose-insulin-potassium reduces infarct size when administered during reperfusion. Cardiovasc Drugs Ther 14:615-623, 2000.
35. Runnman EM, Lamp ST, Weiss JN: Enhanced utilization of exogenous glucose improves cardiac function in hypoxic rabbit ventricle without increasing total glycolytic flux. J Clin Invest 86:1222-1233, 1990.
36. Ulgen MS, Alan S, Akdemir O, et al: The effect of glucose-insulin-potassium solution on ventricular late potentials and heart rate variability in acute myocardial infarction. Coron Artery Dis 12:507-512, 2001.
37. Sun SC, Appleyard R, Masetti P, et al: Improved recovery of heart transplants by combined use of oxygen-derived free radical scavengers and energy enhancement. J Thorac Cardiovasc Surg 104:830-837, 1992.
38. Vanoverschelde JL, Janier MF, Bakke JE, et al: Rate of glycolysis during ischemia determines extent of ischemic injury and functional recovery after reperfusion. Am J Physiol 267:H1785-H1794, 1994.
39. Fath-Ordoubadi F, Beatt KJ: Glucose-insulin-potassium therapy for treatment of acute myocardial infarction: An overview of randomized placebo-controlled trials. Circulation 96:1152-1156, 1997.
40. Eberli FR, Weinberg EO, Grice WN, et al: Protective effect of increased glycolytic substrate against systolic and diastolic dysfunction and increased coronary resistance from prolonged global underperfusion and reperfusion in isolated rabbit hearts perfused with erythrocyte suspensions. Circ Res 68:466-481, 1991.
41. Boros M, Bako L, Nagy S: Effect of antioxidant therapy on cyclooxygenase-derived eicosanoid release during intestinal ischemia-reperfusion. Eur Surg Res 23:141-150, 1991.
42. Akgur FM, Olguner M, Yenici O, et al: The effect of allopurinol pretreatment on intestinal volvulus. J Pediatr Surg 31:1205-1207, 1996.